Equities Analysts Offer Predictions for ARWR Q1 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Tuesday, December 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of $1.63 for the quarter, down from their previous estimate of $1.83. HC Wainwright has a “Buy” rating and a $85.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2027 earnings at ($1.31) EPS.

A number of other equities analysts have also weighed in on ARWR. Royal Bank Of Canada upped their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Bank of America raised their price objective on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.33.

Arrowhead Pharmaceuticals Trading Up 12.3%

Shares of ARWR opened at $65.07 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $66.23. The company has a 50 day simple moving average of $40.78 and a two-hundred day simple moving average of $26.90. The firm has a market cap of $8.84 billion, a P/E ratio of -813.27 and a beta of 1.28.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the third quarter worth $29,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $34,000. Federated Hermes Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Smartleaf Asset Management LLC grew its holdings in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $34,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total transaction of $493,412.50. Following the sale, the director directly owned 68,764 shares in the company, valued at $3,877,601.96. This represents a 11.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. This trade represents a 8.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,750 shares of company stock worth $1,643,413 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.